|
> News
> Events
> Downloads
> Links
Enrolment started in first‑in‑humans study (SIS‑01)
DanTrials has started the enrolment of healthy male and female subjects in a first‑in‑humans study (SIS‑01) investigating a new potential drug for the treatment of COVID-19.
Enrolment started in first‑in‑humans study (KBP‑336‑CD‑001)
DanTrials has started the enrolment of healthy young male subjects in a first‑in‑humans study (KBP‑336‑CD‑001) investigating a new potential drug for the treatment of obesity.
Results of first‑in‑humans study with antiviral candidate for treatment of COVID‑19 published
The results of a first-in-humans study conducted at DanTrials which investigated the safety and tolerability as well as pharmacokinetics of inhaled and intranasal niclosamide have recently been published in The Lancet Regional Health - Europe: A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
Results of first‑in‑humans study in prostate cancer patients published
The results of a first‑in‑humans study conducted at DanTrials where prostate cancer patients were vaccinated against RhoC have recently been published in Journal for ImmunoTherapy of Cancer: Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial
Send an email to info@dantrials.com or give CEO Torben Balchen a call on (+45) 3135 2683 to learn more.
> To top of page
There are no events at the moment.
> To top of page
None available at the moment.
> To top of page
The Danish Medicines Agency
The National Committee on Health Research Ethics
The Danish Data Protection Agency
> To top of page
|
